Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05891171 · ClinicalTrials.gov registry record · Phase 1
Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers
A Phase 1 study of Ovarian Cancer and Bladder Cancer, sponsored by Arcus Biosciences.
- Active
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
- 15
- Study locations
NCT05891171 is a Phase 1 study of Ovarian Cancer and Bladder Cancer that is active but no longer recruiting, run by Arcus Biosciences. The registered enrollment target is 40 participants, below the 729-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (95% lower). The trial reports 15 study locations across 10 states.
The verdict
NCT05891171, a Phase 1 study of Ovarian Cancer and Bladder Cancer, is active but no longer recruiting, sponsored by Arcus Biosciences.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
- 15
- Study locations
Study Summary
The primary purpose of this study is to assess the safety and tolerability of AB598 in participants with advanced malignancies.
Conditions Studied
Interventions
- DRUG Fluorouracil
- DRUG Leucovorin
- DRUG Oxaliplatin
- DRUG Zimberelimab
- DRUG AB598
Study Locations (15)
Other
- Adelaide Cancer Research - Adelaide
- Queen Elizabeth Hospital - Adelaide
- National Cheng Kung University Hospital - Tainan
- Taipei Veterans General Hospital - Taipei
Florida
- Mayo Clinic Florida - Jacksonville
- Lake City Cancer Care, LLC. - Lake City
Ohio
- Gabrail Cancer Center (GCC) Canton Facility - Canton
- University Hospitals Cleveland Medical Center - Cleveland
Arizona
- Mayo Clinic Arizona - Phoenix
Illinois
- Affinity Health Hope and Healing Cancer Services, LLC - Hinsdale
Michigan
- Karmanos Cancer Institute - Detroit
Minnesota
- Mayo Clinic Rochester - Rochester
New Jersey
- Rutgers Cancer Institute of New Jersey - New Brunswick
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2023-10-13 |
| Est. Completion | 2026-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05891171
The ClinicalTrials.gov registry entry for NCT05891171 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 729-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (95% lower). The listed sponsor is Arcus Biosciences, which has 25 total studies on file at ClinicalTrials.gov.
The record links to 10 conditions, with Ovarian Cancer appearing as the primary indexed condition, and to 5 interventions - of which Fluorouracil is the first listed.
NCT05891171 reports 15 study locations spanning 10 distinct geographic areas - top geographies include Other, Florida, Ohio.
Frequently Asked Questions
What is clinical trial NCT05891171 about?
NCT05891171 is a clinical study titled "Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers". The primary purpose of this study is to assess the safety and tolerability of AB598 in participants with advanced malignancies.
What is the current status of trial NCT05891171?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2023-10-13. Estimated completion is 2026-03.
What conditions does trial NCT05891171 study?
This clinical trial studies the following conditions: Ovarian Cancer, Bladder Cancer, Gastric Cancer, Cervical Cancer, Esophageal Cancer.
What interventions are being tested in trial NCT05891171?
The interventions under investigation include: Fluorouracil (DRUG), Leucovorin (DRUG), Oxaliplatin (DRUG), Zimberelimab (DRUG), AB598 (DRUG).
Who is sponsoring clinical trial NCT05891171?
This trial is sponsored by Arcus Biosciences, which has 25 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05891171 being conducted?
This trial has 15 study locations across Arizona, Florida, Illinois, Michigan, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ovarian Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
RECRUITING · Phase 1
-
A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous (IV) ABBV901 Moves Through the Body Alone or in Combination With Bevacizumab in Adult Participants With Ovarian Cancer
RECRUITING · Phase 1
-
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
RECRUITING · Phase 1
-
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.